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The Effect of New Market-Rate
Housing Construction...

likely to be benefits throughout the
region.
However, there are several
shortcomings of the migration chain
mechanism, particularly in the
lowest-cost and most-rent-burdened
neighborhoods. Census tracts in the
bottom fifth of household income
and the top fifth of rent burden
(rent as a share of income) have
an average vacancy rate of 12.8
percent, compared to 8.1 percent
in the rest of my sample. Given
that rents are generally already
low in such neighborhoods, this
suggests that reducing demand
through the migration chain
mechanism is unlikely to lower
costs further, perhaps because rents
have reached the minimum cost of
housing. Moreover, there may also
be important amenity effects if the
migration chain reduces population
in these areas, such as reduced retail
options, school closures, or increased
crime. Vouchers or policies that
lower the cost of housing (such as
reductions in property tax or utility
rates) may be necessary to lower
prices in this segment of the market.
In addition, while I focus on
regional implications, new buildings
could have very different effects on
their immediate area, where they
may change amenities or household
composition in ways that affect prices.
There is little existing direct evidence
on how these factors change following
new construction, and this could be a
fruitful area for future research.
Note
1. I focus on one metropolitan area
because there is large variation across
both race and income in large cities.
Results are similar for other areas.
This article draws on research from an Upjohn Institute
working paper, which can be found at https://research
.upjohn.org/up_workingpapers/307.
Evan Mast is an economist at the Upjohn Institute.
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Medical Innovation
and the Employment
of Cancer Patients
R. Vincent Pohl
Cancer is the second-most common
cause of mortality and morbidity in
developed countries. In addition to its
direct costs in terms of quality-adjusted
life years lost, it also contributes to the
economic costs of disease as cancer
patients often reduce their working
hours or cease employment completely.
Recent decades have seen increased
innovation in the treatment of many
types of cancer. Pharmaceutical
innovation has resulted in new
chemotherapy drugs—often used in
combinations—that are more effective
in targeting tumors while reducing
harm for healthy body tissue. In
addition, new surgical techniques
alleviate side effects and lead to shorter
recovery times.
I investigate whether medical
innovation in the treatment of breast
and prostate cancers, which are the
most common types of cancers among
women and men, respectively, also
lead to a reduction in the economic
costs of cancer. Specifically, I use large
administrative databases from Canada
to estimate how the employment effect
of a cancer diagnosis is moderated
by medical innovation. I employ a
difference-in-differences strategy
combined with matching to estimate
the causal effect of a cancer diagnosis
and how it changes with medical
innovation.

Confirming previous research, I first
find that a cancer diagnosis reduces
employment by 2 to 4 percentage
points. Second, the cumulative
medical innovation that improved
cancer treatment during the 1990s and
2000s led to a decrease in the negative
employment effects of prostate and
breast cancer by about 65 percent.
Hence, the approval of additional drugs
and the introduction of other medical
technologies over this time period are
associated with a substantial reduction
in the economic costs of cancer.
Finally, I consider the employment
effects of cancer diagnoses and
medical innovation by cancer patients’
education. I find that the benefits of
innovation are limited to individuals
with postsecondary education, while
cancer patients with lower levels of
education experience a larger decline in
employment.
From a policy perspective, these
results suggest that innovations in
cancer treatment may provide benefits
beyond direct medical effects. As
innovative cancer treatments can be
very expensive, it is therefore important
to account for economic benefits such
as smaller reductions in labor income
and, as a result, tax revenue when
determining whether the benefits
of a new treatment option outweigh
its cost. The heterogenous effects

ARTICLE HIGHLIGHTS
n Innovations in cancer treatment may alleviate the economic costs of cancer diagnoses, such as a decline of labor supply.
n I find that medical innovation reduces the negative employment effect of cancer
diagnoses by about 65 percent during the study period.
n The economic benefits of medical innovation are limited to cancer patients with
postsecondary education, raising concerns about equal access to new treatments.
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by education indicate that the mere
existence of new medical technology
may not automatically lead to improved
economic outcomes, but rather that
there are barriers to access them.
Background
The most common types of cancers
are breast and prostate, affecting
about 26,000 women and 21,000 men,
respectively, in Canada annually. While
most cancers affect older individuals,
a substantial subgroup of breast and
prostate cancer patients is diagnosed
during their working age. Because
cancer treatment is lengthy and can
cause severe side effects, patients
undergoing treatment often reduce
their labor supply or stop working
completely. These negative labor market
effects may be alleviated by improved
treatment options that are more likely
to cure cancer in a shorter amount of
time and lead to fewer side effects.
To investigate the effect of cancer
diagnoses and medical innovation on
employment, I combine data from
several sources. First, I identify breast
and prostate cancer patients from the
Canadian Cancer Database. Second,
I use individual tax returns from the
Longitudinal Worker File to measure
employment of cancer patients before
and after their diagnosis, as well as
employment of individuals who were
never diagnosed with cancer and who
serve as a control group. Statistics
Canada merged these data sets to the
1991 population census, which contains
individual characteristics such as
educational attainment.
Finally, I measure medical
innovation in two different ways. A
first, more narrow measure is the
number of drugs that are approved for
the treatment of breast and prostate
cancer. Pharmaceutical innovation is
important, as chemotherapy is one of
the main treatment options for cancer.
Throughout the study period, the 1990s
and 2000s, several important new drugs
were approved—the chemotherapy
drug Trastuzumab for the treatment
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of breast cancer, and triptorelin, a
luteinizing hormone-releasing hormone
analogue used to fight prostate cancer.
In addition to chemotherapy,
surgery and radiation are used as cancer
treatment. Notable innovations include
laparoscopic radical prostatectomy, a
minimally invasive surgical technique,
and breast-conserving surgery, both
of which reduce recovery time and
potential side effects after surgery. To
broadly capture innovation in these
areas, I use international patent data.
From these records, I construct a
quality-weighted patent index that
measures the aggregate and cumulative
innovative activity related to breast and
prostate cancer treatment.
Before I estimate the effect of cancer
diagnoses and medical innovation
on employment, I use a matching
technique to create a control group
consisting of individuals without cancer
that is identical to cancer patients along
all observed dimensions. I then employ
a difference-in-differences strategy—I
compare employment rates of cancer
patients and the matched control
group both before and after the cancer
diagnosis. I consider a five-year window

before and after the diagnosis and
allow the employment effects of cancer
diagnoses and medical innovation to
vary over time, as it is plausible that
these effects do not remain constant
within this time frame.
Results
I find that some breast and
prostate cancer patients reduce their
employment after the diagnosis when
compared to the matched control
group. Men are 1.8 percentage points
less likely to be employed after a
prostate cancer diagnosis, and women
are 3.9 percentage points less likely
to be employed after a breast cancer
diagnosis.
Medical innovation substantially
reduces the negative employment
effects of cancer diagnoses. Figure 1
shows the effect of a prostate cancer
diagnosis on employment as a function
of the number of drugs available for the
treatment of this disease. In 1992 when
14 drugs were approved, employment
of prostate cancer patients dropped by a
few percentage points initially, and the
decline reached more than 5 percentage

Figure 1 Effect of Prostate Cancer on Employment by Number of Approved Drugs
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points after three years (blue line; I
show the effects prior to the diagnosis
to rule out any preexisting trends). In
contrast, when 27 approved drugs were
available in 2010, a prostate diagnosis
reduced employment by only about 1
percentage point during the first five
years (red line).
For the employment effects of
breast cancer diagnoses and the role
of medical innovation, Figure 2 shows
a similar pattern. As the number of
drugs approved for the treatment of
breast cancer increased from 17 to 39
between 1992 and 2010, the decline
in employment following a diagnosis
became smaller. At the lowest level
of pharmaceutical innovation, breast
cancer reduces employment by about
2.5 percentage points initially and up to
5 percentage points three years after the
diagnosis and beyond (blue line). At the
highest number of drugs available, the
initial decline in employment is similar,
but after three years, the employment
effect becomes indistinguishable from 0
(red line).
When repeating this exercise with
the quality-weighted patent index
instead of the number of approved

drugs, I find similar patterns (not
shown). Hence, I provide evidence
suggesting that medical innovation in
the form of new drugs and medical
technology alleviates the economic
costs of breast and prostate cancer
diagnoses. On average, medical
innovation reduced the decline in
employment among cancer patients
by about 65 percent between 1992
and 2010. These effects imply that the
annual average earnings losses due to
a prostate and breast cancer diagnosis
are $1,100 and $600, respectively, lower
than they would have been without
medical innovation. Therefore, a
substantial economic benefit arises
from these innovations, in addition to
any resulting reductions in mortality
and morbidity.
To better understand how education
interacts with medical innovation in the
employment of cancer patients, I split
the sample by educational attainment
into individuals without a high school
degree, those who have graduated
from high school but have no further
education, and those with at least some
postsecondary education. Among these
subsamples, I only observe a mitigating

Figure 2 Effect of Breast Cancer on Employment by Number of Approved Drugs
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This is despite the fact that individuals
with lower levels of education reduce
their employment by more than those
with postsecondary education.
Although my data do not allow
me to determine the underlying
mechanism, there are several potential
explanations for the observed
heterogeneity by education. First,
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cancer patients identify medical
providers who use innovative
treatments. Second, education may
enable cancer patients to obtain
information on treatment options and
demand that their medical providers
use up-to-date treatments. Third,
adherence to complex treatment
regimens could be facilitated by higher
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possible that cancer patients with low
education levels work in physically
more demanding jobs where it is
more difficult to undergo a modern
high-intensity cancer treatment while
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the actual mechanism, the fact that only
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innovative cancer treatments suggests
that the economic benefits of medical
innovation are distributed unequally.
Implications
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The empirical findings have several
important implications. First, they
highlight the importance of accounting
for indirect (economic) benefits in a
cost-benefit analysis of new medical
technologies. Although the benefits
in terms of lower earnings losses are
smaller by an order of magnitude than
the annual cost of an intensive cancer
treatment, which can exceed $100,000,
the benefits are substantial. Therefore,
they should be considered in addition
to potential improvements in terms of
mortality and morbidity.
Second, these findings suggest
potential policies that can alleviate
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the economic costs of disease. It is of
particular concern that cancer patients
experience lower employment rates and
hence earnings losses in addition to the
pain and suffering caused by their disease.
Thus, encouraging and subsidizing medical
innovation may have the dual benefit of
mitigating both the medical and economic
consequences of cancer and other diseases.
Investments in research that lead to new
treatment options may very well have a
positive return if the resulting innovation
has economic in addition to medical
benefits.
Last, the fact that medical innovation
does not yield economic gains for cancer
patients with lower levels of education
raises concerns about unequal access to
up-to-date treatment options. Especially
when medical research is publicly
financed, it is reasonable to expect that
resulting innovation should benefit cancer
patients irrespective of their demographic
or socioeconomic background. Moreover,
in the case of the employment effects
of cancer diagnoses, individuals with
the lowest levels of education suffer
the highest economic cost. Therefore,
policymakers may need to ensure that
new and innovative treatment options are
accessible to all patients who would benefit
from them, such as through information
campaigns targeted at these individuals.
In addition, medical education could
increasingly emphasize the importance of
accounting for patients’ socioeconomic
backgrounds in choosing appropriate
cancer treatments.
In sum, these findings highlight the
importance of considering interactions
between labor markets and health care and
point out several policy options aimed at
reducing the economic burden of disease.
This article draws on research from an Upjohn Institute working
paper, which can be found at https://research.upjohn.org/
up_workingpapers/306.
R. Vincent Pohl is an assistant professor at the University of
Georgia.
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New from the Upjohn Press
Food Stamps and the
Working Poor
Peter Mueser, David Ribar, and Erdal Tekin
The authors examine detailed administrative
data from three states—Georgia, Missouri, and
South Carolina—and find that state rules and
regulations often deter eligible low-income
workers from receiving benefits while presenting
hurdles for those who are already eligible to
recertify for
benefits. The
effects of various
certification and
recertification
policies are a key
focus of the book,
but the authors
also discuss the
impacts of the
relaxed provisions
that make it
easier for able-bodied adults without dependents
to receive food stamp benefits. They also
critique a variety of policy proposals to alter the
program, and offer several proposals for making
the program less onerous for working families
and individuals while addressing valid program
concerns.
June 2019
138 pp. $15.00 pbk ISBN 978-88099-660-0.
Also see https://research.upjohn.org/up_
press/256/.

Strengths of the Social
Safety Net in the Great
Recession
Supplemental Nutrition
Assistance and
Unemployment Insurance
Christopher J. O’Leary, David Stevens, Stephen A.
Wandner, and Michael Wiseman, Editors
During the Great Recession, many who lost
their jobs became eligible for Unemployment
Insurance (UI) and often Supplemental Nutrition
Assistance
(SNAP), too.
Many already
receiving SNAP
lost jobs and
became eligible
for UI. While
both programs
were stressed,
they proved
flexible enough
to respond to the
needs of many of the victims of the recession.
But little has been known about how the two
programs interact. The chapters in this book show
that, indeed, each program has considerable
effects on the other and that policies governing
them could be improved. Following chapters
that detail the SNAP and UI programs along with
existing research on their interaction, the editors
use administrative data from six states to reveal
how the programs interact and how they can be
altered to work more effectively.
July 2019
430 pp. $35.00 pbk ISBN 978-0-88099-663-1
PDF is free at https://research.upjohn.org/
up_press/257/.
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